Physician

Anju Vasudevan, M. D.

According to 2025 Medicare claims, Anju Vasudevan, M. D. (NPI: 1043203888) practices hematology/oncology in the Ocala, FL market, with the plurality of this provider's patient population coming from Marion, FL. This provider's primary affiliated billing organization is OCALA ONCOLOGY CENTER PL (NPI: 1356300958; TIN: 900336929) and primary practice location at 34474-4445. Vasudevan is affiliated with the Aledade 154 FL GA MSSP Enhanced (ACO ID: A5357) and Primary Care Alliance, LLC (ACO ID: D0010), participating under both the MSSP and REACH models.

Vasudevan's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,119 traditional Medicare patients, billed 293,578 HCPCS/CPT codes, and received $3,980,025 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,384 prescription claims across 448 beneficiaries totaling $4,801,989 in drug costs, led by Jakafi (Ruxolitinib Phosphate). DME data shows 16 claims. Open Payments data shows 232 records totaling $53,071. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $2,190,316 to $3,980,025. Similarly, Part D prescription costs have moved sharply higher in recent years, from $2,147,147 to $4,801,989. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $1,186 to $0.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	907	299,347	$2,190,316
2016	839	191,615	$2,051,101
2017	1,203	257,788	$2,800,674
2018	1,287	364,269	$3,422,657
2019	1,419	485,538	$5,033,843
2020	1,348	521,210	$5,667,170
2021	1,183	523,860	$4,985,306
2022	1,153	327,307	$4,246,666
2023	1,078	280,433	$4,299,625
2024	1,119	293,578	$3,980,025

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	239	1,505	$2,147,147
2016	228	1,406	$2,058,906
2017	251	1,444	$1,672,629
2018	343	1,890	$1,818,092
2019	381	2,178	$2,098,915
2020	412	2,146	$3,164,365
2021	428	2,018	$3,704,951
2022	460	2,353	$4,659,273
2023	466	2,211	$4,514,515
2024	448	2,384	$4,801,989

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	27	172	$73,838
2016	N/R	118	$46,730
2017	11	42	$7,240
2018	N/R	29	$5,348
2019	12	94	$8,376
2020	N/R	41	$3,827
2021	N/R	12	$230
2022	27	59	$8,284
2023	N/R	N/R	N/R
2024	13	16	$3,589

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	421	663	$90
80053	Blood test, comprehensive group of blood chemicals	702	2,331	$10
36415	Insertion of needle into vein for collection of blood sample	713	3,449	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	701	3,772	$8
83540	Iron level	376	1,286	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jakafi	Ruxolitinib Phosphate	37	1,110	$649,668
Pomalyst	Pomalidomide	17	476	$472,108
Xtandi	Enzalutamide	30	900	$415,154
Cabometyx	Cabozantinib S-Malate	16	480	$396,442
Lenalidomide	Lenalidomide	43	1,169	$382,934

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
L8000	Breast prosthesis, mastectomy bra, without integrated breast prosthesis form, any size, any type	N	13	16	$3,589

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	224	$5,563	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	8	$47,508	ABBVIE INC.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Anju Vasudevan, M. D.?

Tedicare shows public-source Medicare data for Anju Vasudevan, M. D. (NPI 1043203888), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Anju Vasudevan, M. D. have ACO affiliation data?

Anju Vasudevan, M. D. is shown with ACO affiliation data for Aledade 154 FL GA MSSP Enhanced (MSSP, ACO ID A5357) and Primary Care Alliance, LLC (REACH, ACO ID D0010).

What billing organization is linked to Anju Vasudevan, M. D.?

Anju Vasudevan, M. D. is linked to OCALA ONCOLOGY CENTER PL (billing NPI 1356300958) in the available physician profile data.

Does Anju Vasudevan, M. D. have Open Payments data?

Anju Vasudevan, M. D. has 232 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.